Scientists assess synthetic biology's progress and challenges after pioneer's death
Updated
Updated · The Conversation · Apr 30
Scientists assess synthetic biology's progress and challenges after pioneer's death
16 articles · Updated · The Conversation · Apr 30
Following J. Craig Venter's death on 29 April 2026, attention returned to his team's 2010 creation of a cell controlled by a fully synthetic genome.
The field has produced drugs, biofuels and pollution-detecting microbes, but industrial scaling, biological complexity and the inability to build life entirely from nonliving components still limit progress.
Researchers and policymakers also face growing ethical, ecological and biosecurity concerns as gene-editing, DNA synthesis and AI expand the power to redesign organisms.
With synthetic biology advancing and new 'zombie cells' created, how close are we to building life from scratch—and should we?
As AI and biotech merge, who should decide how far humanity goes in engineering life—and what safeguards are truly possible?
With billions invested but few commercial successes, what lessons must synthetic biology learn to fulfill its promise without risking global security?